AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29504781 — intervention group
Group type: COMPARATOR
Intervention: Social Behavior and Network Therapy (SBNT)
Number of subjects: 376
Study 29504781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 376
Study 27780504 — intervention group
Group type: EXPERIMENTAL
Intervention: PFNA combined with zoledronic acid injection (5 mg/100 ml via intravenous drip)
Number of subjects: 60
Study 27780504 — intervention group
Group type: COMPARATOR
Intervention: Control group (PFNA with 600 mg of Caltrate D and 0.25 mg of alpha ossification alcohol)
Number of subjects: 60
Study 25278346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry eye disease patients
Number of subjects: 130
Study 25278346 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 130
Study 23306768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback (BF)
Number of subjects: 46
Study 23306768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training without biofeedback (PFMT)
Number of subjects: 46
Study 20826964 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial ultrasound scanning with a 10-MHz transducer
Number of subjects: 15
Study 20826964 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon's assessment of anastomosis
Number of subjects: 15
Study 20826964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac anesthesiologist's assessment of anastomosis
Number of subjects: 15
Study 18853704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 1 mg once daily for 4 days
Number of subjects: 75
Study 18853704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 2 mg once daily for 4 days
Number of subjects: 75
Study 18853704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg once daily for 4 days
Number of subjects: 75
Study 18853704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 18853704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg once daily for 4 days
Number of subjects: 75
Study 15992726 — intervention group
Group type: EXPERIMENTAL
Intervention: Rounded waveform shocks (50 to 500 V)
Number of subjects: 10
Study 15992726 — intervention group
Group type: COMPARATOR
Intervention: Conventional waveform shocks (50 to 500 V)
Number of subjects: 10
Study 15992726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rounded and conventional waveforms
Number of subjects: 10
Study 14619332 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab, 300 mg, administered subcutaneously every 4 weeks (three injections) for IgE levels < or = 150 IU/mL and every 3 weeks (four injections) for IgE levels > 150 IU/mL.
Number of subjects: 287
Study 10476977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports bra
Number of subjects: 3
Study 10476977 — intervention group
Group type: COMPARATOR
Intervention: Fashion bra
Number of subjects: 3
Study 10476977 — intervention group
Group type: COMPARATOR
Intervention: Crop top
Number of subjects: 3
Study 10476977 — intervention group
Group type: COMPARATOR
Intervention: Bare breasted
Number of subjects: 3
Study 8733926 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong cue group (context words, line drawings, and stems of target words)
Number of subjects: 0
Study 8733926 — intervention group
Group type: COMPARATOR
Intervention: Weak cue group (context words and stems of target words without line drawings)
Number of subjects: 0
Study 1747004 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of fluconazole daily for 12 weeks
Number of subjects: 25
Study 1747004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1747004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (open phase)
Number of subjects: 25
Study 1747004 — intervention group
Group type: COMPARATOR
Intervention: No fluconazole treatment
Number of subjects: 25
Study 6341070 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (PHT, 200 mg/day)
Number of subjects: 6
Study 6341070 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (PHT, 300 mg/day)
Number of subjects: 6
Study 6341070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ, 600 mg/day)
Number of subjects: 6
Study 6341070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ, 800 mg/day)
Number of subjects: 6
Study 6608483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (50,000 IU p.o. two to three times weekly)
Number of subjects: 56
Study 6608483 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-OH-D (20 to 50 mg p.o. daily as required)
Number of subjects: 56
Study 6608483 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplemental vitamin D treatment)
Number of subjects: 56
Study 31549935 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic radical cystectomy
Number of subjects: 302
Study 31549935 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 302
Study 29283597 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week, group-based parenting program (ADAPT)
Number of subjects: 336
Study 29283597 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 336
Study 28139626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution, 1 time per day for 10 days (G1)
Number of subjects: 40
Study 28139626 — intervention group
Group type: COMPARATOR
Intervention: 200 ml 0.9% NaCl solution (G2)
Number of subjects: 40
Study 24925592 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes
Number of subjects: 272
Study 24925592 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-requiring gestational diabetes
Number of subjects: 272
Study 24925592 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic control in gestational diabetes
Number of subjects: 272
Study 22154591 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy plus adjuvant chemotherapy
Number of subjects: 508
Study 22154591 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone
Number of subjects: 508
Study 21084077 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine awareness and intention to become vaccinated
Number of subjects: 2295
Study 21084077 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of HPV vaccine by ethnicity
Number of subjects: 2295
Study 21084077 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to be vaccinated by ethnicity
Number of subjects: 2295
Study 21084077 — intervention group
Group type: EXPERIMENTAL
Intervention: Education's effect on awareness and intention
Number of subjects: 2295
Study 21084077 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness and desire for vaccination by language spoken at home
Number of subjects: 2295
Study 18689368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose plus 2.4 g amino acids . kg(‐1) . d(‐1)
Number of subjects: 20
Study 18689368 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (control group)
Number of subjects: 20
Study 15714185 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine/0.5 mg mL(‐1) sufentanil
Number of subjects: 20
Study 15714185 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine alone
Number of subjects: 20
Study 12798823 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2028
Study 12798823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2028
Study 10226122 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with thermal balloon ablation (single intramuscular administration of GnRH analog)
Number of subjects: 30
Study 10226122 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with thermal balloon ablation (without uterine preparation)
Number of subjects: 30
Study 10226122 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 30
Study 10226122 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 30
Study 8911942 — intervention group
Group type: EXPERIMENTAL
Intervention: Illusory change in size (brought about by presenting five converging lines in two different configurations under the disks)
Number of subjects: 8
Study 8911942 — intervention group
Group type: COMPARATOR
Intervention: Control (no illusory change in size)
Number of subjects: 8
Study 1881743 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous varicella vaccine
Number of subjects: 166
Study 1881743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular varicella vaccine
Number of subjects: 166
Study 1881743 — intervention group
Group type: COMPARATOR
Intervention: Both routes (subcutaneous and intramuscular)
Number of subjects: 166
Study 6178592 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte IFN
Number of subjects: 0
Study 6178592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast IFN
Number of subjects: 0
Study 30768060 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMPO protocol
Number of subjects: 122
Study 30768060 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocols (Control)
Number of subjects: 122
Study 28746164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine intravaginal ring
Number of subjects: 0
Study 28746164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26037514 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal insulin injection before a high-carbohydrate meal
Number of subjects: 10
Study 26037514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose meal
Number of subjects: 10
Study 26037514 — intervention group
Group type: COMPARATOR
Intervention: Control meal with premeal saline injection
Number of subjects: 10
Study 24432671 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyan Zhitong Paste (XZP), applied externally, one to two pastes each time, exchanged once per 24 hours, for a total of two 7-day treatment courses.
Number of subjects: 0
Study 24432671 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied externally in the same manner as XZP.
Number of subjects: 0
Study 22208289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategic practice change intervention implemented across all facilities to facilitate clinician risk assessment and provision of brief advice and referral.
Number of subjects: 56
Study 22208289 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews with randomly selected clients who visited a community health facility in the last two weeks.
Number of subjects: 56
Study 22208289 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews with randomly selected samples of clinicians from each facility group before and after the intervention.
Number of subjects: 56
Study 19922896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fixed-dose formulation of ticlopidine 250 mg/ginkgo extract 80 mg
Number of subjects: 24
Study 19922896 — intervention group
Group type: COMPARATOR
Intervention: Concomitant administration of ticlopidine 250 mg and ginkgo extract 80 mg
Number of subjects: 24
Study 16990077 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (cholinesterase inhibitor)
Number of subjects: 769
Study 16990077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study 15131408 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist genetics assessment
Number of subjects: 412
Study 15131408 — intervention group
Group type: COMPARATOR
Intervention: Assessment by a breast surgeon (control)
Number of subjects: 412
Study 15131408 — intervention group
Group type: EXPERIMENTAL
Intervention: Further counselling and testing within families
Number of subjects: 412
Study 11600101 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 55
Study 11600101 — intervention group
Group type: COMPARATOR
Intervention: Subgroup of patients hospitalized for less than 2 months after antipsychotic medications were restored
Number of subjects: 55
Study 10423601 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg once daily
Number of subjects: 272
Study 10423601 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 30 mg once daily
Number of subjects: 272
Study 10423601 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 272
Study 10423601 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 272
Study 10423601 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg + Hydrochlorothiazide 25 mg
Number of subjects: 272
Study 10423601 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 30 mg + Hydrochlorothiazide 50 mg
Number of subjects: 272
Study 10423601 — intervention group
Group type: COMPARATOR
Intervention: Moexipril monotherapy
Number of subjects: 272
Study 10423601 — intervention group
Group type: COMPARATOR
Intervention: Diuretic or combination treatment
Number of subjects: 272
Study 7943382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (2 min)
Number of subjects: 9
Study 7943382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress test (2 min of mental arithmetic)
Number of subjects: 9
Study 3359909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fat (Intralipid 10%)
Number of subjects: 9
Study 3359909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fat (Intralipid 10%)
Number of subjects: 9
Study 3359909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fat plus cholestyramine (20 g)
Number of subjects: 9
Study 3359909 — intervention group
Group type: EXPERIMENTAL
Intervention: All fat infusion groups (Intravenous and Intraduodenal)
Number of subjects: 9
Study 3359909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fat (group IV)
Number of subjects: 9
Study 31698977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless porous-coated hemispherical cups with electrochemically applied hydroxyapatite (BoneMaster) coating (PBM)
Number of subjects: 53
Study 31698977 — intervention group
Group type: COMPARATOR
Intervention: Cementless porous-coated hemispherical cups with porous coating alone (P)
Number of subjects: 53
Study 31698977 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM cups
Number of subjects: 53
Study 31698977 — intervention group
Group type: COMPARATOR
Intervention: P cups
Number of subjects: 53
Study 31526690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function Neuro‐QoL in pediatric patients with Sturge‐Weber syndrome
Number of subjects: 22
Study 31526690 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 22
Study 31526690 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of skin involvement
Number of subjects: 22
Study 31526690 — intervention group
Group type: EXPERIMENTAL
Intervention: Total eyelid port-wine birthmark
Number of subjects: 22
Study 31526690 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye involvement
Number of subjects: 22
Study 31526690 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sturge‐Weber syndrome involvement
Number of subjects: 22
Study 31526690 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at seizure onset
Number of subjects: 22
Study 31526690 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 22
Study 28215316 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia extract (500 mg daily)
Number of subjects: 49
Study 28215316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 25199912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low external resistance (40% of 1-repetition maximum)
Number of subjects: 52
Study 25199912 — intervention group
Group type: EXPERIMENTAL
Intervention: High external resistance (70% of 1-repetition maximum)
Number of subjects: 52
Study 23811808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 9
Study 23811808 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 9
Study 23811808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21523338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg BID
Number of subjects: 79
Study 21523338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg BID
Number of subjects: 79
Study 21523338 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg QD
Number of subjects: 79
Study 17700649 — intervention group
Group type: COMPARATOR
Intervention: 3 meals/day (3M)
Number of subjects: 140
Study 17700649 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 meals and 3 snacks/day (3+3M)
Number of subjects: 140
Study 16514304 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 4295
Study 12899109 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir with nucleoside-analogue reverse-transcriptase inhibitors (NRTI)
Number of subjects: 3
Study 12899109 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir with zidovudine and lamivudine
Number of subjects: 3
Study 12899109 — intervention group
Group type: COMPARATOR
Intervention: NRTI monotherapy
Number of subjects: 3
Study 12899109 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 3
Study 10872898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day)
Number of subjects: 30
Study 10872898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamins E and C
Number of subjects: 30
Study 10872898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g/day)
Number of subjects: 30
Study 10872898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9354709 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty combined with stenting (ST)
Number of subjects: 51
Study 9354709 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty alone (BA)
Number of subjects: 51
Study 8401167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by general practitioners (GP) for smoking cessation
Number of subjects: 450
Study 3093045 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder by the nurse
Number of subjects: 939
Study 3093045 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal reminder by the physician
Number of subjects: 939
Study 3093045 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder by letter
Number of subjects: 939
Study 3093045 — intervention group
Group type: COMPARATOR
Intervention: No reminder (Control group)
Number of subjects: 939
Study 3093045 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients contacted by nurse
Number of subjects: 939
Study 3093045 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients seen by physician
Number of subjects: 939
Study 31937350 — intervention group
Group type: EXPERIMENTAL
Intervention: c-MeST (computerised memory specificity training)
Number of subjects: 0
Study 31937350 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29939894 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular analgesic injection (PAI)
Number of subjects: 40
Study 29939894 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 40
Study 26932345 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL), administered subcutaneously, following a placebo control through weeks 16 and 24.
Number of subjects: 0
Study 24576514 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine manual aspiration thrombectomy with the Export catheter during PPCI
Number of subjects: 10700
Study 24576514 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention alone
Number of subjects: 10700
Study 22691654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nonsteroidal anti‐inflammatory drug (NSAID)
Number of subjects: 59
Study 22691654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin
Number of subjects: 59
Study 22691654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) 10% mannitol and steroid
Number of subjects: 59
Study 22691654 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 20% mannitol and steroid with oral gabapentin
Number of subjects: 59
Study 20038515 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-D (anthracyclines plus docetaxel)
Number of subjects: 1996
Study 20038515 — intervention group
Group type: COMPARATOR
Intervention: FEC100 (anthracyclines alone)
Number of subjects: 1996
Study 18272891 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg intravenous on days 1 and 15)
Number of subjects: 104
Study 18272891 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 104
Study 18272891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 16204792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal histamine (4 mg/ml, 0.1 ml)
Number of subjects: 14
Study 16204792 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 14
Study 16204792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal histamine
Number of subjects: 14
Study 16204792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intensified breathing
Number of subjects: 14
Study 14576754 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mug folic acid/day
Number of subjects: 121
Study 14576754 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pyridoxine/day
Number of subjects: 121
Study 14576754 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121
Study 10665894 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg controlled-release formulation)
Number of subjects: 34
Study 10665894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8717596 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMX (160/800 mg) daily
Number of subjects: 0
Study 8717596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (300 mg) monthly
Number of subjects: 0
Study 8717596 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 8390084 — intervention group
Group type: EXPERIMENTAL
Intervention: calcitonin
Number of subjects: 50
Study 8390084 — intervention group
Group type: EXPERIMENTAL
Intervention: calcitonin+fluoride
Number of subjects: 50
Study 8390084 — intervention group
Group type: COMPARATOR
Intervention: calcium+vitamin D supplements
Number of subjects: 50